Cargando…
S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428374/ http://dx.doi.org/10.1097/01.HS9.0000968120.02996.d3 |
| _version_ | 1785090453691957248 |
|---|---|
| author | Carpenedo, Monica Broome, Catherine M Mcdonald, Vickie Miyakawa, Yoshitaka Kuter, David Al-Samkari, Hanny Bussel, James Matthijssens, Filip Hultberg, Anna Ayguasanosa Dachs, Jaume De Beuf, Kristof Rodeghiero, Francesco Michel, Marc Newland, Adrian |
| author_facet | Carpenedo, Monica Broome, Catherine M Mcdonald, Vickie Miyakawa, Yoshitaka Kuter, David Al-Samkari, Hanny Bussel, James Matthijssens, Filip Hultberg, Anna Ayguasanosa Dachs, Jaume De Beuf, Kristof Rodeghiero, Francesco Michel, Marc Newland, Adrian |
| author_sort | Carpenedo, Monica |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428374 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283742023-08-17 S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY Carpenedo, Monica Broome, Catherine M Mcdonald, Vickie Miyakawa, Yoshitaka Kuter, David Al-Samkari, Hanny Bussel, James Matthijssens, Filip Hultberg, Anna Ayguasanosa Dachs, Jaume De Beuf, Kristof Rodeghiero, Francesco Michel, Marc Newland, Adrian Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428374/ http://dx.doi.org/10.1097/01.HS9.0000968120.02996.d3 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Carpenedo, Monica Broome, Catherine M Mcdonald, Vickie Miyakawa, Yoshitaka Kuter, David Al-Samkari, Hanny Bussel, James Matthijssens, Filip Hultberg, Anna Ayguasanosa Dachs, Jaume De Beuf, Kristof Rodeghiero, Francesco Michel, Marc Newland, Adrian S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_full | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_fullStr | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_full_unstemmed | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_short | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_sort | s302: long-term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the advance+ study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428374/ http://dx.doi.org/10.1097/01.HS9.0000968120.02996.d3 |
| work_keys_str_mv | AT carpenedomonica s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT broomecatherinem s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT mcdonaldvickie s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT miyakawayoshitaka s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT kuterdavid s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT alsamkarihanny s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT busseljames s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT matthijssensfilip s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT hultberganna s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT ayguasanosadachsjaume s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT debeufkristof s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT rodeghierofrancesco s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT michelmarc s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT newlandadrian s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy |